Medical Pharmacology: Chapter 31 — Gonadal and Ovarian Pharmacology -- Module 4 — Ovulation Induction, ART Pharmacology, and Ovarian Hyperstimulation

Chapter 31 — Gonadal and Ovarian Pharmacology — Module 4 — Ovulation Induction, ART Pharmacology, and Ovarian Hyperstimulation

1. A 30-year-old woman with PCOS and a 16-month history of anovulatory infertility has completed three ovulatory cycles on clomiphene citrate. Ultrasound confirmed ovulation in each cycle, but serial monitoring showed a persistently thin endometrium (peak 6 mm) and her partner's semen analysis is normal. She has no tubal disease. She remains motivated to pursue oral therapy before considering injectable gonadotropins. Which of the following is the most appropriate next step, and why?

A) Continue clomiphene at the same dose for three more cycles, because cumulative pregnancy rates with clomiphene continue to rise substantially beyond six ovulatory cycles and the thin endometrium will improve with continued exposure.
B) Switch to letrozole, because it induces follicular development by aromatase inhibition rather than estrogen receptor blockade, leaving the endometrium responsive to follicle-derived estradiol and thereby correcting the thin-endometrium problem that is limiting her chance of conception on clomiphene.
C) Add a gonadotropin-releasing hormone (GnRH) agonist to the clomiphene regimen, because pituitary downregulation will improve endometrial receptivity while preserving the ovulation already achieved on clomiphene.
D) Begin human chorionic gonadotropin (hCG) injections in the follicular phase, because the thin endometrium reflects inadequate luteinizing hormone activity that hCG will supply, thickening the endometrium.
E) Proceed directly to in vitro fertilization, because a thin endometrium on clomiphene is an absolute indication for IVF and no further oral or injectable ovulation induction is appropriate.

ANSWER: B

Rationale:

This patient is ovulating on clomiphene but has a thin endometrium, the classic manifestation of clomiphene's peripheral anti-estrogenic effect: clomiphene occupies estrogen receptor alpha throughout the body, and even when hypothalamic blockade successfully drives ovulation, the same receptor occupancy in the endometrium prevents follicle-derived estradiol from producing normal endometrial proliferation. The most appropriate next step in a patient who wishes to continue oral therapy is to switch to letrozole, which induces follicular development by inhibiting aromatase (lowering estradiol synthesis) rather than by blocking estrogen receptors; because the receptors remain unoccupied, the endometrium responds normally to the estradiol produced by the developing follicle, correcting the thin-endometrium problem that is limiting conception. Letrozole is the evidence-supported preferred agent in PCOS and directly addresses the mechanism of her treatment failure.

Option A: Option A is incorrect because cumulative clomiphene pregnancy rates plateau after approximately three to six ovulatory cycles rather than continuing to rise substantially, and continued clomiphene exposure does not improve and may worsen the anti-estrogenic thin endometrium.
Option C: Option C is incorrect because adding a GnRH agonist would suppress gonadotropin secretion and is not a treatment for clomiphene-related endometrial thinning; it does not restore endometrial receptivity and would undermine the ovulation already achieved.
Option D: Option D is incorrect because the thin endometrium reflects estrogen receptor blockade by clomiphene, not a luteinizing hormone deficiency; follicular-phase hCG does not correct anti-estrogenic endometrial thinning and is not used as a follicular endometrial agent.
Option E: Option E is incorrect because a thin endometrium on clomiphene is not an absolute indication for IVF; a trial of letrozole, which addresses the mechanism directly, is the appropriate less-invasive next step in a patient with isolated ovulatory dysfunction and no other infertility factors.

2. A 28-year-old woman with PCOS (body mass index 34 kg/m^2) presents for ovulation induction after failing to conceive over a year of attempts. Her primary care physician previously prescribed clomiphene, on which she ovulated inconsistently without pregnancy. She asks specifically which oral agent gives her the best chance of a live birth. Which of the following is the most appropriate response and the evidence basis for it?

A) Clomiphene should simply be restarted at a higher dose, because in obese PCOS patients clomiphene at 150 mg consistently outperforms all other oral agents for live birth.
B) Metformin monotherapy should be used as the primary ovulation induction agent, because in obese PCOS patients metformin produces higher live birth rates than any other oral ovulation induction strategy.
C) No oral agent is appropriate at this body mass index, and she should proceed directly to gonadotropin injections, because oral ovulation induction agents are ineffective in women with a body mass index above 30 kg/m^2.
D) Letrozole is the preferred oral agent, because a large randomized trial conducted by the NICHD Reproductive Medicine Network in women with PCOS demonstrated higher live birth and ovulation rates with letrozole than with clomiphene, an advantage that was particularly evident in obese patients.
E) Tamoxifen should be selected over both clomiphene and letrozole, because as a selective estrogen receptor modulator it has been shown in randomized trials to produce the highest live birth rates of any ovulation induction agent in PCOS.

ANSWER: D

Rationale:

For a woman with PCOS seeking the oral agent that offers the best chance of live birth, letrozole is the preferred choice, supported by high-quality randomized evidence. The NICHD Reproductive Medicine Network trial (Legro and colleagues) randomized women with PCOS to letrozole versus clomiphene and demonstrated significantly higher cumulative live birth and ovulation rates with letrozole; the advantage was particularly notable among obese patients, making letrozole especially appropriate for this woman with a body mass index of 34 kg/m^2. Mechanistically, letrozole's aromatase inhibition leaves the endometrium and cervix responsive to follicle-derived estradiol and produces predominantly monofollicular ovulation, contributing to its superior outcomes.

Option A: Option A is incorrect because clomiphene does not consistently outperform letrozole in obese PCOS patients; the randomized evidence shows letrozole produces higher live birth rates, and simply escalating clomiphene is not the best strategy for this patient.
Option B: Option B is incorrect because metformin monotherapy does not produce higher live birth rates than letrozole in PCOS; metformin may have adjunctive roles related to insulin resistance but is not the primary ovulation induction agent of choice for maximizing live birth.
Option C: Option C is incorrect because oral ovulation induction agents are not ineffective above a body mass index of 30 kg/m^2; letrozole in particular retains efficacy and is preferred in obese PCOS patients, so proceeding directly to gonadotropins is not required.
Option E: Option E is incorrect because tamoxifen has not been shown to produce the highest live birth rates of any ovulation induction agent in PCOS; letrozole is the evidence-supported preferred oral agent, and tamoxifen is not standard first-line therapy for this indication.

3. A 25-year-old competitive distance runner with a body mass index of 17 kg/m^2 has had amenorrhea for two years. Laboratory evaluation shows undetectable LH, low FSH, and low estradiol, consistent with WHO Group I anovulation (hypogonadotropic hypogonadism). After nutritional counseling, she desires pregnancy and gonadotropin ovulation induction is planned. Which gonadotropin preparation is most appropriate for her, and why?

A) A preparation providing both FSH and LH activity (human menopausal gonadotropin, or recombinant FSH combined with recombinant LH), because in hypogonadotropic hypogonadism the absence of endogenous LH means theca cells cannot generate the androgen substrate that granulosa cell aromatase requires, so LH activity must be supplied alongside FSH to achieve adequate estradiol production.
B) Highly purified urinary FSH alone, because FSH stimulates granulosa cells directly and is sufficient to drive estradiol synthesis regardless of the patient's LH status.
C) Recombinant FSH alone, because recombinant FSH preparations contain enough residual LH activity to support theca cell function in hypogonadotropic patients.
D) Clomiphene citrate, because blocking estrogen negative feedback will restore her endogenous gonadotropin secretion and correct the hypogonadotropic state.
E) hCG alone administered throughout the follicular phase, because hCG provides sustained LH-receptor stimulation that replaces the need for FSH in driving follicular development.

ANSWER: A

Rationale:

This patient has WHO Group I anovulation (hypogonadotropic hypogonadism) from functional hypothalamic suppression, with undetectable LH. This is the specific clinical setting in which the choice of gonadotropin preparation is decisive. By the two-cell, two-gonadotropin model, LH stimulates theca cells to produce androgen substrate (androstenedione and testosterone), which granulosa cell aromatase then converts to estradiol under FSH stimulation. Because she has negligible endogenous LH, an FSH-only preparation would recruit follicular growth but could not generate adequate estradiol owing to absent androgen substrate. She therefore requires a preparation providing both FSH and LH activity — human menopausal gonadotropin (which contains LH/hCG bioactivity) or recombinant FSH combined with recombinant LH.

Option B: Option B is incorrect because highly purified urinary FSH provides essentially no LH activity, and in the absence of endogenous LH it cannot support the theca androgen production required for estradiol synthesis in this hypogonadotropic patient.
Option C: Option C is incorrect because recombinant FSH preparations are produced free of LH activity and contain no meaningful residual LH; recombinant FSH must be combined with recombinant LH for the hypogonadotropic patient.
Option D: Option D is incorrect because clomiphene requires an intact hypothalamic-pituitary axis capable of increased gonadotropin output when negative feedback is blocked; in a hypogonadotropic patient with an underactive axis there is no endogenous secretion to disinhibit, so clomiphene is ineffective.
Option E: Option E is incorrect because hCG provides only LH-receptor stimulation and cannot replace FSH; follicular development and granulosa cell function require FSH-receptor stimulation, so hCG alone would not drive the FSH-dependent steps of follicular growth and estrogen synthesis.

4. A 32-year-old woman is on day 6 of FSH stimulation for IVF using a GnRH antagonist protocol. Monitoring shows a leading follicle of 14 mm and a rapidly rising serum estradiol. The supervising physician notes that the patient has not yet started her GnRH antagonist. Which of the following is the most appropriate action at this point, and what is the rationale?

A) Withhold the antagonist until the leading follicle reaches at least 18 mm, because introducing it now would suppress FSH and arrest follicular growth before the cohort is mature.
B) Administer a GnRH agonist now to downregulate the pituitary, because at this follicle size the priority is deep pituitary suppression to prevent a premature surge.
C) Begin the GnRH antagonist now, because at this stage of stimulation the rising estradiol and the 14 mm leading follicle create a risk of a premature LH surge, and the antagonist produces immediate competitive blockade of pituitary GnRH receptors without an initial flare, preventing premature ovulation while exogenous FSH continues follicular development.
D) Trigger ovulation immediately with hCG, because a 14 mm leading follicle with rising estradiol indicates the cohort is mature and ready for retrieval.
E) Discontinue FSH for 48 hours (coast) before starting the antagonist, because the antagonist cannot be introduced while FSH is being administered.

ANSWER: C

Rationale:

In a GnRH antagonist protocol, the antagonist is introduced during the mid-to-late follicular phase precisely when the developing cohort begins to pose a risk of a premature LH surge — typically when the leading follicle reaches approximately 13 to 14 mm or serum estradiol rises above a surge-risk threshold. This patient, on day 6 with a 14 mm leading follicle and rapidly rising estradiol, is exactly at that point. The correct action is to begin the antagonist now: GnRH antagonists produce immediate competitive blockade of pituitary GnRH receptors with no initial stimulatory flare, so they can be started mid-stimulation to prevent a premature LH surge while exogenous FSH continues to drive follicular development toward maturity.

Option A: Option A is incorrect because waiting until 18 mm would leave the patient unprotected against a premature LH surge during the high-risk window; the antagonist does not arrest follicular growth, because exogenous FSH continues to drive the cohort, and pituitary FSH suppression is irrelevant when FSH is being supplied exogenously.
Option B: Option B is incorrect because administering a GnRH agonist now would cause an initial flare and is not how surge prevention is achieved in an antagonist protocol; the antagonist, not an agonist, is the appropriate agent for immediate surge prevention at this stage.
Option D: Option D is incorrect because a 14 mm leading follicle is not mature; triggering now would retrieve immature oocytes, and the cohort requires further growth before triggering.
Option E: Option E is incorrect because the antagonist can be introduced while FSH is being administered; there is no need to coast or discontinue FSH, and doing so would needlessly interrupt follicular development.

5. A 27-year-old woman with PCOS (AMH 7.0 ng/mL, antral follicle count 33) is planning IVF. In a prior fresh-transfer cycle at another center she developed severe early-onset OHSS requiring hospitalization. She is determined to minimize OHSS risk this time. Which overall cycle plan most comprehensively reduces her OHSS risk at each decision point?

A) A long GnRH agonist protocol with a high starting FSH dose, hCG trigger, and fresh embryo transfer, because deep pituitary suppression provides the strongest protection against recurrent OHSS in high responders.
B) A GnRH antagonist protocol with a high starting FSH dose, hCG trigger, and fresh transfer with intramuscular progesterone, because the antagonist protocol alone is sufficient to prevent OHSS regardless of the trigger and transfer choices.
C) A GnRH antagonist protocol with a low starting FSH dose, hCG trigger, and fresh transfer, because lowering the FSH dose alone eliminates OHSS risk and allows a fresh transfer to proceed safely.
D) A long GnRH agonist protocol with a low starting FSH dose, GnRH agonist trigger, and freeze-all, because combining downregulation with an agonist trigger maximizes OHSS prevention.
E) A GnRH antagonist protocol with a low starting FSH dose, a GnRH agonist trigger in place of hCG, and a freeze-all strategy with deferred frozen embryo transfer, because each element independently lowers OHSS risk: low-dose FSH limits the recruited cohort, the agonist trigger produces only a short endogenous LH surge, and freeze-all avoids the rising endogenous pregnancy hCG that drives late OHSS.

ANSWER: E

Rationale:

This high-responder PCOS patient with a prior severe OHSS episode requires a plan that layers protective choices at every decision point, and the antagonist-based plan does exactly that. A GnRH antagonist protocol preserves pituitary responsiveness, enabling a GnRH agonist trigger. A low starting FSH dose limits the size of the recruited follicular cohort and thus the number of corpora lutea producing VEGF. The GnRH agonist trigger replaces hCG with a short-lived endogenous LH surge, sharply reducing early OHSS risk. A freeze-all strategy defers transfer to a later programmed cycle, so no pregnancy occurs in the stimulated cycle and the rising endogenous hCG that drives late OHSS is avoided. Together these provide near-complete OHSS protection.

Option A: Option A is incorrect because it selects the highest-risk combination for this patient: the long agonist protocol forecloses the agonist trigger, high-dose FSH over-recruits her large cohort, and hCG trigger with fresh transfer maximizes both early and late OHSS risk.
Option B: Option B is incorrect because the antagonist protocol alone, when paired with high-dose FSH, an hCG trigger, and fresh transfer, does not adequately prevent OHSS; the protective benefit requires the accompanying low-dose FSH, agonist trigger, and freeze-all.
Option C: Option C is incorrect because lowering the FSH dose alone, while still using an hCG trigger and fresh transfer, does not eliminate OHSS risk in a high responder; the hCG trigger and a fresh-cycle pregnancy can still drive OHSS.
Option D: Option D is incorrect because a long agonist protocol cannot accommodate a GnRH agonist trigger — the downregulated pituitary cannot mount an LH surge — so this combination is internally inconsistent and not feasible as described.

6. A 33-year-old woman undergoing IVF has multiple mature follicles and receives her hCG trigger injection at 9:00 PM on Monday. The nurse coordinator is scheduling her oocyte retrieval. The patient asks why the retrieval cannot simply be done first thing the next morning, about 12 hours after the trigger, for her convenience. Which of the following is the correct retrieval timing and the physiologic explanation to give her?

A) Retrieval should be performed about 12 hours after the trigger, as she suggests, because oocyte maturation is complete by then and any further delay risks losing the oocytes to spontaneous ovulation.
B) Retrieval should be performed approximately 34 to 36 hours after the trigger, because the hCG trigger replicates the LH surge that drives resumption of oocyte meiosis and cumulus expansion, with follicular rupture occurring at about 34 to 36 hours; retrieval is timed just before expected rupture so the oocytes are mature but not yet released, which is why a 12-hour retrieval would yield immature oocytes.
C) Retrieval timing is flexible within the first 72 hours after the trigger, because the hCG signal sustains follicular maturity throughout that period and the oocytes remain mature and retrievable at any point within it.
D) Retrieval should be performed exactly 24 hours after the trigger, matching the duration of the natural LH surge, because oocyte maturation is synchronized to a precise 24-hour interval.
E) Retrieval should be performed 48 to 72 hours after the trigger, because full cytoplasmic maturation requires this longer interval and earlier retrieval consistently yields immature oocytes.

ANSWER: B

Rationale:

The standard trigger-to-retrieval interval is approximately 34 to 36 hours. The hCG trigger replicates the physiologic mid-cycle LH surge, which sets in motion resumption of oocyte meiosis from prophase I arrest, cumulus expansion, and follicular wall remodeling, culminating in follicular rupture at roughly 34 to 36 hours. Retrieval is deliberately scheduled just before expected rupture, so the oocytes have completed trigger-induced maturation but have not yet been released from the follicle. Performing the retrieval about 12 hours after the trigger, as this patient requests, would be far too early — the oocytes would not have completed maturation and the yield of mature, fertilizable oocytes would be poor.

Option A: Option A is incorrect because 12 hours is too early; oocyte maturation is not complete at that point, and the concern at 12 hours is immaturity, not spontaneous ovulation, which does not occur until near the 34-to-36-hour mark.
Option C: Option C is incorrect because retrieval timing is not flexible across 72 hours; follicular rupture occurs at about 34 to 36 hours, after which spontaneous ovulation would release the oocytes and make retrieval impossible.
Option D: Option D is incorrect because the interval is approximately 34 to 36 hours, not 24 hours; the time from surge onset to follicular rupture is longer than the surge itself, so a 24-hour retrieval would be premature.
Option E: Option E is incorrect because 48 to 72 hours is too late; by that time spontaneous ovulation would already have occurred and the oocytes could not be retrieved.

7. A 35-year-old woman is scheduled for a fresh embryo transfer and requires luteal phase support. In her previous cycle she received intramuscular progesterone-in-oil and developed painful injection-site nodules and a sterile abscess that required management. She is anxious about repeating the injections and asks whether an equally effective alternative exists. Which of the following is the most appropriate recommendation and its pharmacologic justification?

A) She must continue intramuscular progesterone-in-oil despite the reactions, because no alternative route achieves endometrial progesterone concentrations adequate to support implantation.
B) She should switch to oral micronized progesterone, because oral dosing achieves the highest endometrial progesterone concentrations of any route through efficient hepatic activation.
C) She should be switched to luteal support with estradiol rather than progesterone, because estrogen is the principal hormone required for secretory endometrial maintenance during the luteal phase.
D) She should switch to vaginal progesterone, because vaginal administration delivers progesterone to the uterus via a uterine first-pass effect that produces high endometrial concentrations, providing effective luteal support while avoiding the pain and local reactions of intramuscular oil-based injections.
E) She should discontinue luteal support entirely, because in fresh ART cycles the multiple corpora lutea produce sufficient endogenous progesterone and supplementation is unnecessary.

ANSWER: D

Rationale:

This patient needs effective luteal support but cannot tolerate intramuscular progesterone-in-oil. Vaginal progesterone is the preferred alternative for most patients and is well suited here. Its pharmacologic basis is the uterine first-pass effect: progesterone administered vaginally reaches the uterus directly through local diffusion and utero-vaginal venous and lymphatic connections, producing high endometrial tissue concentrations even when systemic serum levels are lower than with intramuscular dosing. This provides effective endometrial secretory support for implantation while avoiding the pain, nodules, and sterile abscesses associated with intramuscular oil injections — exactly the complications she experienced.

Option A: Option A is incorrect because intramuscular progesterone-in-oil is not the only adequate route; vaginal progesterone provides effective endometrial support, so a poorly tolerated regimen need not be continued.
Option B: Option B is incorrect because oral micronized progesterone undergoes extensive hepatic first-pass metabolism that lowers bioavailability and produces lower, less reliable endometrial concentrations than the vaginal route, so it does not achieve the highest endometrial concentrations and is not preferred for luteal support.
Option C: Option C is incorrect because progesterone, not estradiol, is the principal hormone required for secretory transformation and maintenance of the luteal endometrium; estradiol may be used adjunctively in some protocols but does not replace progesterone for luteal support.
Option E: Option E is incorrect because luteal support is mandatory in fresh ART cycles; GnRH analog co-administration suppresses endogenous LH and produces luteal phase deficiency, so the corpora lutea do not reliably produce sufficient progesterone and supplementation cannot be omitted.

8. A 29-year-old woman underwent IVF with an hCG trigger and a fresh embryo transfer. She had mild abdominal bloating in the first week after retrieval that was improving. On day 13 after retrieval she returns with worsening abdominal distension, tense ascites, hematocrit 49%, reduced urine output, and a positive serum pregnancy test with a rising beta-hCG. Which of the following best characterizes her condition and the implication for her clinical course?

A) She has late-onset OHSS driven by rising endogenous hCG from the established pregnancy; because the pregnancy-derived hCG continues to rise through early gestation, late OHSS tends to be more severe and prolonged than early OHSS and warrants close monitoring with supportive management, including attention to fluid balance, paracentesis for tense ascites, and thromboprophylaxis, as the pregnancy progresses.
B) She has early-onset OHSS from the trigger injection; because trigger hCG has a short half-life, her symptoms will resolve within 24 to 48 hours without intervention regardless of the pregnancy.
C) Her presentation is a normal physiologic response to early pregnancy and does not represent OHSS, because OHSS cannot occur once a pregnancy is established and the corpus luteum is rescued.
D) She has late-onset OHSS, but because it is pregnancy-related it is self-limited and milder than early OHSS, typically resolving within 2 to 3 days as implantation completes.
E) Her presentation is unrelated to OHSS and most likely represents ovarian torsion, because ascites and distension two weeks after retrieval are not features of any form of OHSS.

ANSWER: A

Rationale:

This is late-onset OHSS. The diagnostic features are the timing (onset 10 or more days after retrieval, here day 13), the initial improvement of early symptoms followed by worsening, and — most tellingly — a positive and rising serum pregnancy test. Late OHSS is driven by rising endogenous hCG produced by the implanting embryo, which provides a sustained and escalating LH-receptor stimulus to the multiple corpora lutea, re-driving VEGF-mediated vascular permeability. The clinical implication is that, unlike early OHSS (driven by the single trigger hCG dose, which clears over days), late OHSS is fueled by an hCG signal that continues to climb through early pregnancy and therefore tends to be more severe and more prolonged, requiring close monitoring and supportive management — fluid and electrolyte management, paracentesis for tense ascites, and thromboprophylaxis — over a protracted course.

Option B: Option B is incorrect because this is late, not early, OHSS; the day-13 onset, the rising pregnancy test, and the worsening after initial improvement indicate an endogenous hCG-driven process that will not resolve in 24 to 48 hours.
Option C: Option C is incorrect because OHSS can certainly occur after pregnancy is established; the rising endogenous hCG of early pregnancy is the cause of late OHSS, not a protective factor.
Option D: Option D is incorrect because late OHSS is generally more severe and prolonged than early OHSS, not milder and self-limited, because the rising endogenous hCG sustains and worsens the process rather than allowing resolution within days.
Option E: Option E is incorrect because ascites and worsening distension with a rising pregnancy test two weeks after retrieval are characteristic of late OHSS; while ovarian torsion must be considered if pain is acute and focal, the described picture is classic for late OHSS rather than unrelated to it.

9. A 30-year-old woman at moderately elevated OHSS risk is undergoing IVF. For reasons related to her luteal support plan, the team has decided to use an hCG trigger rather than a GnRH agonist trigger, accepting some hCG luteotropic activity. To mitigate OHSS risk in this setting, the physician plans to add cabergoline 0.5 mg daily for 8 days beginning on the day of trigger. Which of the following best describes the role and mechanism of cabergoline in this clinical context?

A) Cabergoline is being used to suppress prolactin so that the corpora lutea produce more progesterone, and this improved luteal function indirectly stabilizes the ovarian vasculature to reduce OHSS.
B) Cabergoline can replace all other OHSS-prevention measures and is sufficient as sole prophylaxis to eliminate severe OHSS risk even when an hCG trigger is used.
C) Cabergoline serves as adjunctive OHSS prophylaxis: as a dopamine D2 receptor agonist it acts on endothelial dopamine receptors to interfere with VEGF receptor-2 phosphorylation and downstream signaling, reducing the vascular permeability that produces OHSS without substantially impairing pregnancy rates, which is why it is added rather than relied on alone.
D) Cabergoline reduces OHSS risk by lowering circulating VEGF concentrations through inhibition of VEGF synthesis in luteinized granulosa cells, thereby removing the ligand that drives vascular permeability.
E) Cabergoline prevents OHSS by directly antagonizing LH receptors on the corpora lutea, blocking the hCG signal that drives VEGF production.

ANSWER: C

Rationale:

Cabergoline is a dopamine D2 receptor agonist used as adjunctive prophylaxis against OHSS, and it is particularly relevant in a patient receiving an hCG trigger who therefore retains meaningful luteotropic hCG activity. Its OHSS-preventive mechanism operates at the endothelial VEGF receptor: dopamine D2 receptor activation interferes with the phosphorylation and downstream signaling of VEGF receptor-2 (VEGFR2), through which VEGF increases vascular permeability. By blunting VEGFR2 signaling, cabergoline decreases the vascular permeability that produces the third-space fluid shifts of OHSS. It reduces the incidence and severity of early OHSS in high-risk patients without substantially impairing implantation or pregnancy rates, which is why it is used as an adjunct rather than as a stand-alone solution.

Option A: Option A is incorrect because cabergoline's OHSS-preventive effect is not mediated through prolactin suppression improving luteal progesterone; although it lowers prolactin, its relevant action here is dopaminergic interference with endothelial VEGFR2 signaling.
Option B: Option B is incorrect because cabergoline is an adjunct that reduces but does not eliminate OHSS risk; it does not replace primary strategies such as the agonist trigger and freeze-all and is not sufficient as sole prophylaxis when an hCG trigger is used.
Option D: Option D is incorrect because cabergoline does not principally lower circulating VEGF concentrations by inhibiting VEGF synthesis; its established mechanism is interference with VEGFR2 phosphorylation and signaling at the endothelium — it blunts the response to VEGF rather than removing the ligand.
Option E: Option E is incorrect because cabergoline does not antagonize LH receptors on the corpora lutea; it acts downstream at the endothelial VEGFR2 level via dopamine D2 receptors and does not block the hCG-LH receptor interaction that drives VEGF production.

10. A 28-year-old woman is hospitalized with severe OHSS: tense ascites causing abdominal pain and respiratory splinting, hematocrit 50%, oliguria, and bilaterally enlarged ovaries. Her serum pregnancy test is positive. The team is establishing her management plan. Which of the following sets of interventions correctly reflects the priorities in her care?

A) Aggressive high-dose intravenous furosemide to treat the oliguria, hypotonic fluid replacement to match the protein-rich third-space losses, and avoidance of paracentesis because removing ascitic fluid is contraindicated in OHSS.
B) Strict fluid restriction to limit further third-space accumulation, empiric broad-spectrum antibiotics for presumed infected ascites, and combined oral estrogen-progestin therapy to suppress the corpora lutea.
C) Hypotonic intravenous fluids to correct hyponatremia, diuretics to relieve the tense ascites, and withholding of any anticoagulation because pregnancy contraindicates thromboprophylaxis.
D) Immediate cabergoline as the primary treatment to reverse established OHSS, high-volume crystalloid boluses to rapidly normalize the hematocrit regardless of the ascites, and avoidance of paracentesis.
E) Isotonic crystalloid for judicious volume resuscitation (avoiding hypotonic fluids), ultrasound-guided paracentesis to relieve the tense ascites and improve respiratory mechanics and renal perfusion, and low-molecular-weight heparin thromboprophylaxis to address the markedly increased venous thromboembolism risk, which is a leading cause of OHSS death.

ANSWER: E

Rationale:

The management of severe OHSS targets the consequences of VEGF-driven plasma extravasation while avoiding interventions that worsen the fluid shifts or thrombotic risk. Judicious volume resuscitation uses isotonic crystalloid (normal saline or a balanced isotonic solution), which expands the intravascular compartment without the osmolar problems of hypotonic fluids; hypotonic fluids are avoided. For tense ascites causing pain, respiratory compromise, or oliguria from raised intra-abdominal pressure, ultrasound-guided paracentesis is therapeutic — relieving pain, improving diaphragmatic excursion and respiratory mechanics, and improving renal perfusion. Critically, low-molecular-weight heparin thromboprophylaxis is essential: the convergence of hemoconcentration (hematocrit 50%), immobility, and the prothrombotic milieu of early pregnancy markedly increases venous thromboembolism risk, and thromboembolism is a leading cause of OHSS mortality. Together, isotonic fluids, paracentesis, and LMWH represent the core priorities.

Option A: Option A is incorrect because high-dose furosemide is generally contraindicated in the hypovolemic, hemoconcentrated OHSS patient (it worsens hemoconcentration and thrombotic risk), hypotonic fluids are avoided, and paracentesis is in fact a valuable therapeutic measure rather than contraindicated.
Option B: Option B is incorrect because strict fluid restriction is inappropriate in a hypovolemic, oliguric patient, the ascites is not presumed infected so empiric antibiotics are not a priority, and estrogen-progestin therapy is neither effective for OHSS nor appropriate in a pregnant patient.
Option C: Option C is incorrect because hypotonic fluids are avoided, diuretics worsen the intravascular depletion, and pregnancy does not contraindicate thromboprophylaxis — low-molecular-weight heparin is in fact indicated to address the elevated thrombotic risk.
Option D: Option D is incorrect because cabergoline is a prophylactic adjunct given around the time of trigger, not a primary treatment that reverses established severe OHSS, and aggressive crystalloid boluses aimed solely at normalizing the hematocrit while ignoring the tense ascites are not appropriate; paracentesis is beneficial rather than to be avoided.

11. A 40-year-old woman with diminished ovarian reserve (AMH 0.3 ng/mL, antral follicle count 4) is beginning IVF. A trainee proposes a low starting FSH dose of 75 IU per day, reasoning that this will reduce cost and OHSS risk. The supervising physician disagrees with this dosing approach for this particular patient. Which of the following is the most appropriate FSH dosing strategy and the counseling that should accompany it?

A) Use a low starting FSH dose of 75 IU per day as the trainee suggests, because poor responders are highly FSH-sensitive and low doses maximize their oocyte yield while minimizing OHSS risk.
B) Use a high starting FSH dose (300 to 450 IU per day) to maximally recruit her limited follicular pool, while counseling her that even with high-dose stimulation the oocyte yield is likely to remain low, because exogenous FSH can only recruit follicles that already exist within her diminished antral pool and cannot create additional follicles.
C) Use a standard 150 IU per day dose identical to that used for high responders, because the FSH starting dose does not need to be individualized to ovarian reserve.
D) Withhold gonadotropin stimulation entirely and counsel her that diminished ovarian reserve is an absolute contraindication to stimulation, so only donor oocytes can be offered.
E) Use minimal stimulation with 37.5 IU per day plus clomiphene, because this reliably produces more oocytes than high-dose gonadotropins in poor responders and should always be preferred in diminished reserve.

ANSWER: B

Rationale:

FSH starting dose is individualized to ovarian reserve, and this patient with diminished reserve (very low AMH and low antral follicle count) is a poor responder for whom a low 75 IU dose would be inappropriate. The correct strategy is a high starting FSH dose (commonly 300 to 450 IU per day) to maximally recruit her limited follicular pool. The essential accompanying counseling point is realistic expectation-setting: exogenous FSH can only recruit follicles that already exist within the antral pool — it cannot create new follicles beyond her reserve — so even maximal stimulation is likely to yield a low number of oocytes. The high dose optimizes recruitment within that biological ceiling rather than overcoming it.

Option A: Option A is incorrect because it inverts the relationship between reserve and dosing: poor responders with diminished reserve require high, not low, FSH doses, and the rationale that low doses suit highly FSH-sensitive ovaries describes the high-responder situation, not diminished reserve.
Option C: Option C is incorrect because the FSH starting dose should be individualized to ovarian reserve; a single standard dose across all patients would underdose poor responders such as this woman.
Option D: Option D is incorrect because diminished ovarian reserve is not an absolute contraindication to stimulation; many such patients still attempt stimulation with their own oocytes before considering donor oocytes, which is a separate counseling discussion rather than a mandatory exclusion.
Option E: Option E is incorrect because minimal stimulation does not reliably produce more oocytes than high-dose gonadotropins in poor responders; it is an alternative that accepts low yield for lower cost and burden but is not established to outperform high-dose stimulation for oocyte number and is not a mandatory preferred approach in all diminished-reserve patients.